NexStar Pharm(NXTR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NexStar Pharm(NXTR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (296)	8/17/1998 11:13:00 PM
From: Steven Yang	Read Replies (1) of 328

MZ, I too view this news as a positive one. Near term, this deal validates the PASS technology, and hopefully, adds some of the much needed credit to NXTR management. long term, with the help of the German partner and its marketing muscle, NXTR could develop PASS and the speciality chemistry expertise into a viable business. From the operational point of view, with this deal, NXTR could start to be profittable in 98Q3 due to the reduce R&D cost and interest expenses. Interesting enough, the street did not take this news positive -- NXTR went down while the market went up today. Steven

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next